Launch New Illumina MiSeq DNA Sequencing Service

2 July 2012

Source BioScience plc

('Source BioScience', the 'Group')

Source BioScience Launches New Illumina MiSeq™ Next Generation DNA Sequencing Service

Sole UK commercial provider, extending next generation sequencing service for customers

Source BioScience plc (LSE: SBS), the European leader in DNA sequencing and genomic services, announces the launch of an extended next generation sequencing service using the new Illumina MiSeq™ technology platform.

The launch of the MiSeq™ service establishes Source BioScience as the only commercial provider of this new technology in the UK, maintaining the Group's position at the forefront of sequencing services as well as affirming it as the largest UK provider of Illumina sequencing.

The MiSeq™ service addresses the "middle ground" between the Group's existing Overnight Service for sequencing and the ultra high throughput HiSeq™ service, enabling access to new markets and customers for next generation sequencing.

The MiSeq™ presents significant opportunities for the Group's Healthcare division, applying next generation sequencing to molecular diagnostics, a key component of the business. The latest developments in cancer diagnostics and personalised treatment for patients are aimed at creating integrated genetic tests that characterise cancers at the molecular level to improve diagnosis and treatment outcome.

Dr Nick Ash, CEO of Source BioScience said: "The MiSeq™ offers rapid turnaround times for next generation sequencing, enabling scientists to access an increasing range of sequencing applications, which will attract new customers to our LifeSciences services.

"In addition, the introduction of the MiSeq™ is instrumental in realising the aims of the Technology Strategy Board grant awarded to Source BioScience in 2011. Under this grant, Source BioScience is collaborating with a number of international partners to develop an integrated genetic test to personalise the diagnosis and treatment of cancers."

--- ENDS ---

For further information, please contact:

Source BioScience plc

Dr Nick Ash, CEO

Tel: +44 (0) 115 973 9010

Email: [email protected]

www.sourcebioscience.com

College Hill (PR Agency to Source BioScience)

Melanie Toyne-Sewell/Jayne Crook

Tel: +44 (0)207 457 2020

Email: [email protected]

About Source BioScience:

Source BioScience plc (LSE: SBS) is an international diagnostics and genetic analysis business serving the healthcare and research markets. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. The Company is a trusted provider of a complete range of sophisticated microarray, next generation and conventional sequencing services. GLP, GCP and CPA accreditations make the sequencing offerings also very attractive for applications in regulatory studies or clinical settings. Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. The Group has its headquarters in Nottingham, UK. Further information about Source BioScience can be found at www.sourcebioscience.com